CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know


    This story originally appeared on Zacks

    In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day. The stock outpaced the S&P 500’s daily gain of 0.62%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.03%.

    – Zacks

    Heading into today, shares of the company had gained 1.52% over the past month, lagging the Medical sector’s gain of 2.92% and outpacing the S&P 500’s gain of 0.87% in that time.

    Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.74, down 16% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 million, up 1356.22% from the year-ago period.

    For the full year, our Zacks Consensus Estimates are projecting earnings of $5 per share and revenue of $905.71 million, which would represent changes of +194.52% and +125869.62%, respectively, from the prior year.

    Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.

    Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

    Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.

    Digging into valuation, CRISPR Therapeutics AG currently has a Forward P/E ratio of 16.44. Its industry sports an average Forward P/E of 23.51, so we one might conclude that CRISPR Therapeutics AG is trading at a discount comparatively.

    The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 37% of all 250+ industries.

    The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

    To follow CRSP in the coming trading sessions, be sure to utilize

    More Stock News: This Is Bigger than the iPhone!

    It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

    Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2022.

    Click here for the 4 trades >>

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
    CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
    To read this article on click here.
    Zacks Investment Research

    Source link


    Please enter your comment!
    Please enter your name here